Skip to main content
SpringerLink
Log in
Book cover

Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease pp 115–126Cite as

Eptifibatide in Coronary Intervention—The IMPACT Trials

  • Chapter

  • 56 Accesses

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

While percutaneous transluminal coronary intervention has revolutionized the management of patients with coronary artery disease, this technological advance is neither innocuous nor a panacea. In addition to the technical limitations of the procedure, it is now well recognized that serious vascular injury is caused by the treatment device that creates a perfect milieu for coronary thrombosis (1–3). Clinical trials of the monoclonal antibody abciximab (c7E3 Fab; ReoProTM, Eli Lilly and Company [Indianapolis, IN]/Centocor [Malvern, PA]) directed at the platelet glycoprotein (GP) lib/Illa integrin have clearly documented that inhibition of this receptor during coronary intervention reduces thrombotic complications and improves clinical outcomes (4–8). These positive clinical trial results, coupled with a clearer understanding of platelet physiology, have stimulated the search and encouraged the development of other parenteral inhibitors of the GP IIb/IIIa receptor.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Neuhaus KL, Zeymer U. Prevention and management of thrombotic complications during coronary interventions. Eur Heart J 1995; 16 (suppl L): L63–67.

    Article  Google Scholar 

  2. Wilentz JR, Sanborn TA, Haudenschild CC, et al. Platelet accumulation in experimental angioplasty: time-course and relation to vascular injury. Circulation 1987; 76: 1225–1234.

    Google Scholar 

  3. Steele PM, Chesebro JH, Stanson AW, Holmes DR Jr, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105–112.

    Article  PubMed  CAS  Google Scholar 

  4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/ IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956–961.

    Article  Google Scholar 

  5. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wand AL, Miller DP, Anderson KM, Califf RM. Long-term protection from myocardial ischemic events in a randomized trial of brief Integrin (33 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479–484.

    Article  PubMed  CAS  Google Scholar 

  6. The EPILOG Investigators. Platelet glycoprotein IIb/Ills receptor blockade and low dose heparin during percutaneous coronary revascularisation. N Engl J Med 1997; 336: 1689–1696.

    Article  Google Scholar 

  7. Lincoff AM, Tcheng JE, Califf RM, et al Standard versus low dose weight adjusted heparin in patients treated with the platelet glycoprotein Ilb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularisation. The PROLOG investigators. Am J Cardiol 1997; 79: 286–291.

    Article  PubMed  CAS  Google Scholar 

  8. The CAPTURE Investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429–1435.

    Article  Google Scholar 

  9. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553–1559.

    Article  PubMed  CAS  Google Scholar 

  10. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71: 831–843.

    PubMed  CAS  Google Scholar 

  11. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: a member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559–1562.

    Article  PubMed  CAS  Google Scholar 

  12. Mustard JF, Kinlough-Rathbone RL, Packham MA. Comparison of fibrinogen association with normal and thrombasthenic platelets on exposure to ADP or Chymotrypsin. Blood 1979; 54: 987–993.

    PubMed  CAS  Google Scholar 

  13. Dennis MS, Henzel WJ, Pitti RM, et al. Platelet glycoprotein IIb/IIIa protein antagonists from snake venoms: evidence for a family of platelet aggregation inhibitors. (ArgGlyAsp/fibrinogen receptor/ trigramin/echistatin/kistrin). Proc Natl Acad Sci USA 1989; 87: 2471–2475.

    Article  Google Scholar 

  14. Scarborough RM, Naughton MA, Teng W. Design of potent and specific integrin antagonists with high specificity for glycoprotein IIb/IIIa. J Biol Chem 1993; 268: 1066–1073.

    PubMed  CAS  Google Scholar 

  15. Charo IF, Scarborough RM, Du Mee CP, et al. Therapeutics I: pharmacodynamics of the glycoprotein IIb/IIIa antagonist integrelin: phase 1 clinical studies in normal healthy volunteers. Circulation 1992; 86 (suppl I): I - 260.

    Google Scholar 

  16. Scarborough RM, Rose JW, Hsu MA. Barbourin. A GPIIb/IIIa-specific integrin antagonist from the venom of Sistrurus m barbouri. J Biol Chem 1991; 266: 9359–9362.

    PubMed  CAS  Google Scholar 

  17. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 1995; 76: 2151–2157.

    Article  Google Scholar 

  18. Harrington RA, Klieman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222–1227.

    Article  PubMed  CAS  Google Scholar 

  19. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997; 349: 1422–1428.

    Article  Google Scholar 

  20. Lincoff AM, Tcheng JE, Ellis SG, Moliterno DJ, Kitt MM, Debowey D, Topol EJ, for the IMPACT II Investigators. Randomized trial of platelet glycoprotein IIb/IIIa inhibition with integrelin for prevention of restenosis following coronary intervention: the IMPACT II angiographic substudy. Circulation(suppl) 1995; 92: I - 2905.

    Google Scholar 

  21. Phillips DR, Teng W, Arfsten A, et al. Effect of calcium on GP IIb/IIIa interactions with Integrilinenhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96: 1488–1494.

    Article  PubMed  CAS  Google Scholar 

  22. Tcheng JE. Glycoprotein IIb/IIIa inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996; 78 (suppl 3A): 35–40.

    Article  PubMed  CAS  Google Scholar 

  23. Tcheng JE, Thel MC, Jennings L, et al. Platelet glycoprotein IIb/IIIa receptor blockade with high dose IntegrilinTM in coronary intervention. Results of the PRIDE Study. Eur Heart J 1997; 18: P3615.

    Google Scholar 

  24. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–443.

    Article  Google Scholar 

  25. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–1453.

    Article  Google Scholar 

Download references

Authors
  1. Conor O’Shea MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James E. Tcheng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Experimental Interventional Laboratory, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    A. Michael Lincoff MD (Associate Professor of Medicine. Director) (Associate Professor of Medicine. Director)

  2. Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    A. Michael Lincoff MD (Associate Professor of Medicine. Director) & Eric J. Topol MD (Professor of Medicine, Chairman. Director) (Associate Professor of Medicine. Director) &  (Professor of Medicine, Chairman. Director)

  3. Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Eric J. Topol MD (Professor of Medicine, Chairman. Director) (Professor of Medicine, Chairman. Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

O’Shea, C., Tcheng, J.E. (1999). Eptifibatide in Coronary Intervention—The IMPACT Trials. In: Lincoff, A.M., Topol, E.J. (eds) Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-724-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-724-6_6

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6202-0

  • Online ISBN: 978-1-59259-724-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation